World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
143
Citations
111118
World Ranking
147
National Ranking
2

Medicine

D-Index
143
Citations
113600
World Ranking
1468
National Ranking
44

Overview

David A. Cooper was affiliated with the University of New South Wales in Australia. Their primary field of study was Medicine, with a focus on subfields including Infectious Diseases, Epidemiology, Animal Science and Zoology, Cardiology and Cardiovascular Medicine, and Health.

The main topics covered in their research included:

  • SARS-CoV-2 and COVID-19 Research
  • Respiratory viral infections research
  • Viral gastroenteritis research and epidemiology
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 detection and testing
  • Animal Virus Infections Studies
  • Influenza Virus Research Studies

David A. Cooper contributed articles to several frequent publication venues, including:

  • New England Journal of Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Open Forum Infectious Diseases
  • Nature
  • The Journal of Infectious Diseases

Some of the recent papers associated with their research included:

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, 2020, New England Journal of Medicine
  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, 2020, New England Journal of Medicine
  • COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses, 2020, Nature
  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, 2020, Nature
  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents, 2021, New England Journal of Medicine

Frequent coauthors included:

  • Kena A. Swanson
  • Alejandra Gurtman
  • Uğur Şahin
  • William C. Gruber
  • Philip R. Dormitzer

Best Publications

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

    Fernando P. Polack;Stephen J. Thomas;Nicholas Kitchin;Judith Absalon

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • CD4+ count-guided interruption of antiretroviral treatment.

    Wafaa El-Sadr;Wafaa El-Sadr;Jens D Lundgren;James Neaton;Fred Gordin

  • Initiation of antiretroviral therapy in early asymptomatic HIV infection

    Sean Emery;Shweta Sharma;Gerd Fätkenheuer;Josep M. Llibre

  • A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

    Andrew Carr;Katherine Samaras;Samantha Burton;Matthew Law

  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

    Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  • COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.

    Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler

  • Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study

    Andrew Carr;Katherine Samaras;Anna Thorisdottir;Gilbert R Kaufmann

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

    Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  • Adverse effects of antiretroviral therapy

    Andrew Carr;David A Cooper;David A Cooper

  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell

  • Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

    Andrew Carr;Katherine Samaras;Donald J Chisholm;David A Cooper

  • Acute AIDS Retrovirus Infection. Definition of a Clinical Illness Associated With Seroconversion

    DavidA. Cooper;DavidA. Cooper;DavidA. Cooper;Prudence Maclean;Prudence Maclean;Prudence Maclean;Robert Finlayson;Robert Finlayson;Robert Finlayson;HarryM. Michelmore;HarryM. Michelmore;HarryM. Michelmore

  • A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

    Julio S. G. Montaner;Peter Reiss;David Cooper;Stefano Vella

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel

    Patrick G. Yeni;Scott M. Hammer;Charles C. J. Carpenter;David A. Cooper

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

    Adriano Lazzarin;Bonaventura Clotet;David Cooper;Jacques Reynes

  • Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

    Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell

  • A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

    Andrew Carr;John Miller;Matthew Law;David A. Cooper

  • BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

    Ugur Sahin;Alexander Muik;Isabel Vogler;Evelyna Derhovanessian

Frequent Co-Authors

Anthony D. Kelleher
Anthony D. Kelleher University of New South Wales
Andrew Carr
Andrew Carr University of Oxford
Sean Emery
Sean Emery University of New South Wales
Matthew Law
Matthew Law University of New South Wales
John Zaunders
John Zaunders Ascension Health
Ronald Penny
Ronald Penny University of New South Wales
John M. Kaldor
John M. Kaldor University of New South Wales
Kiat Ruxrungtham
Kiat Ruxrungtham Chulalongkorn University
Janaki Amin
Janaki Amin Macquarie University
Joep M. A. Lange
Joep M. A. Lange University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Immunology in the USA opens doors to diverse healthcare careers, especially in nursing specialties focused on immune-related disorders. Many students consider pursuing an easy nurse practitioner programs to get into as a practical entry point, balancing accessibility with quality education. These programs can provide foundational clinical skills applicable to immunology-related fields.

For those interested in mental health and immune system connections, the best online psychiatric mental health nurse practitioner programs offer specialized training alongside strong clinical placement opportunities. This pathway is excellent for students seeking hands-on experience while studying remotely.

Budget-friendly options are also available. Students looking for cost-effective education might explore the cheapest online pmhnp programs, which provide reputable credentials without the financial burden.

Career prospects post-degree are promising, with many graduates advancing to earn a Doctor of Nursing Practice (DNP). Understanding the doctor of nursing practice salary by state can help students make informed decisions about where to study and work within the USA.

Best Scientists Citing David A. Cooper

Recently Published Articles